

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

### **翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

## **VOLUNTARY ANNOUNCEMENT**

### **LICENSING AGREEMENT WITH KEROS**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on December 12, 2021 (EST), Hansoh (Shanghai) Healthtech Company Limited\* (翰森(上海)健康科技有限公司) (“**Hansoh Healthtech**”), a wholly-owned subsidiary of the Company, entered into an exclusive license agreement (the “**Licensing Agreement**”) with Keros Therapeutics, Inc. (Nasdaq: KROS) (“**Keros**”).

Pursuant to the Licensing Agreement, Hansoh Healthtech obtained an exclusive license from Keros to develop, manufacture and commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau (collectively, the “**Territory**”). Hansoh Healthtech will be responsible for the development, regulatory approval and commercialization of KER-050 in the Territory, and will pay a US\$20 million upfront payment and potential payments upon reaching development and commercial milestones of up to US\$170.5 million, plus double digit tiered royalties on net product sales.

KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis.

Keros is a clinical-stage biopharmaceutical company focused on hematological and musculoskeletal disorders. To the best knowledge and belief of the Company, Keros is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under Listing Rules.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, December 13, 2021

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* *For identification purposes only*